<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Diabetes Mellitus | The Pharm Bible</title>

  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600&family=Parisienne&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="style.css">
</head>
<body>

<header>
  <h1 class="main-title">Diabetes Mellitus</h1>
  <p class="subtitle">Type 1 & Type 2</p>
</header>

<main class="disease-page">

  <!-- GUIDELINES -->
  <section>
    <h2>Guidelines</h2>
    <ul class="guidelines">
      <li>American Diabetes Association – Standards of Care 2024</li>
      <li>American Association of Clinical Endocrinology – 2023 Algorithm</li>
      <li>American Heart Association – Cardiovascular Risk in Diabetes</li>
    </ul>
  </section>

  <!-- PATHOPHYSIOLOGY -->
  <section>
    <h2>Pathophysiology</h2>

    <h3>Type 1 Diabetes</h3>
    <ul>
      <li>Autoimmune beta-cell destruction</li>
      <li>Absolute insulin deficiency</li>
      <li>High risk of diabetic ketoacidosis (DKA)</li>
      <li>Requires lifelong insulin therapy</li>
    </ul>

    <h3>Type 2 Diabetes</h3>
    <ul>
      <li>Insulin resistance + progressive beta-cell dysfunction</li>
      <li>Relative insulin deficiency</li>
      <li>Associated with obesity and metabolic syndrome</li>
      <li>Gradual onset with microvascular and macrovascular risk</li>
    </ul>
  </section>

  <!-- TREATMENT ALGORITHM -->
  <section>
    <h2>Treatment Algorithm</h2>

    <h3>Type 1</h3>
    <ul>
      <li>Initiate insulin at diagnosis</li>
      <li>Basal + bolus regimen preferred</li>
      <li>Consider insulin pump (CSII)</li>
      <li>Continuous glucose monitor (CGM) strongly recommended</li>
      <li>A1c goal generally &lt; 7% (individualize)</li>
    </ul>

    <h3>Type 2 (ADA-Based)</h3>
    <ul>
      <li>Start lifestyle modification + metformin unless contraindicated</li>
      <li>If ASCVD → GLP-1 receptor agonist or SGLT2 inhibitor with CV benefit</li>
      <li>If heart failure → SGLT2 inhibitor preferred</li>
      <li>If CKD → SGLT2 inhibitor if eGFR adequate</li>
      <li>If A1c ≥10% or symptomatic → consider insulin</li>
      <li>Add additional agents if not at goal</li>
    </ul>
  </section>

  <!-- DRUG THERAPY -->
  <section>
    <h2>Drug Therapy</h2>

    <div class="drug-block">
      <h3>metformin (Glucophage, Glucophage XR)</h3>
      <p><strong>Class:</strong> Biguanide</p>
      <p><strong>Indication:</strong> First-line therapy in Type 2 diabetes</p>
      <p><strong>Dose:</strong> 500 mg twice daily; titrate up to 2000 mg/day</p>
      <p><strong>MOA:</strong> Decreases hepatic glucose production</p>
      <p><strong>Side Effects:</strong> GI upset, diarrhea, nausea</p>
      <p><u><strong>Black Box:</strong></u></p>
      <ul>
        <li>Lactic acidosis</li>
      </ul>
      <p><strong>Contraindications:</strong> eGFR &lt; 30 mL/min/1.73m²</p>
      <p><strong>Pearls:</strong> Weight neutral; may decrease B12 levels; hold with contrast studies</p>
    </div>

    <div class="drug-block">
      <h3>insulin glargine (Lantus, Basaglar)</h3>
      <p><strong>Class:</strong> Long-acting insulin</p>
      <p><strong>Indication:</strong> Type 1 and Type 2 diabetes</p>
      <p><strong>Dose:</strong> 10 units daily or 0.1–0.2 units/kg/day</p>
      <p><strong>MOA:</strong> Provides basal insulin coverage</p>
      <p><strong>Side Effects:</strong> Hypoglycemia, weight gain</p>
      <p><strong>Contraindications:</strong> Hypoglycemia</p>
      <p><strong>Pearls:</strong> No pronounced peak; once-daily dosing</p>
    </div>

  </section>

</main>

</body>
</html>
